Search - tctmd.com

Displaying 201 - 220 of 692

Sort: Relevancy | Date

Presentation TCT 2024

1-Year and Landmark 6-12 Month Clinical Outcomes Among Patients in Complex Lesion Subsets Treated With DynamX Bioadaptor Compared to a Contemporary DES From the INFINITY-SWEDEHEART Randomized Clinical Trial

Presenter: David Erlinge

October 28, 2024

Presentation TCT 2024

Artificial-Intelligence Enabled Quantitative CT Assessment of Atherosclerosis and Major Adverse Events: The Multi-Center International CONFIRM2 Registry

Presenter: Alexander Van Rosendael

October 28, 2024

Presentation TCT 2024

Too Good to Be True? Five Top Lessons of Major GLP-1 Agonists Trials

Presenter: C. Michael Gibson

October 27, 2024

Presentation ESC 2024

BedMed and BedMed-Frail randomized controlled trials

Presenter: Scott Garrison

August 31, 2024

Presentation NY Valves 2024

Mid-term Outcomes of Balloon Expandable TAVR for the Treatment of Failed Bioprosthetic Valves in the United States

Presenter: Tsuyoshi Kaneko

June 07, 2024

Presentation NY Valves 2024

Transcatheter Edge-to-Edge Repair vs Transcatheter Mitral Valve Replacement in Patients With Primary Mitral Regurgitation and Red Zone Anatomy: A Propensity Score-Matched Analysis

Presenter: Sebastian Ludwig

June 07, 2024

Presentation NY Valves 2024

Evaluating Mitral TEER in the Management of Moderate Mitral Regurgitation Among Heart Failure Patients

Presenter: Anita W. Asgar

June 07, 2024

Presentation NY Valves 2024

Impact of Bioprosthetic Valve Performance on 5-year Clinical Outcomes in Patients at Intermediate or Greater Surgical Risk

Presenter: Steven J. Yakubov

June 07, 2024

Presentation NY Valves 2024

UPDATES: Pre-emptive AVR Clinical Trials for Moderate and Severe AS

Presenter: Philippe Pibarot

June 07, 2024

Presentation NY Valves 2024

Managing Multi-Valvular Disease and Considerations for Surgical Eligibility

Presenter: Joshua Goldberg

June 07, 2024

Presentation NY Valves 2024

Assessing Functional Status and Predicting Clinical Improvement

Presenter: Suzanne V. Arnold

June 07, 2024

Presentation NY Valves 2024

The Importance of Baseline Hemodynamics and Tricuspid Anatomy

Presenter: Philipp Lurz

June 07, 2024

Presentation NY Valves 2024

Real World TTVI Registries: Is There Concordance With the Randomized Trials?

Presenter: Bassem M. Chehab

June 07, 2024

Presentation NY Valves 2024

T-TEER - TRILUMINATE

Presenter: Brian K. Whisenant

June 07, 2024

Presentation NY Valves 2024

Transcatheter Tricuspid Valve Replacement - TRISCEND II

Presenter: Raj Makkar

June 07, 2024

Presentation NY Valves 2024

Pre-emptive AVR for Moderate AS and Asymptomatic Severe AS: A Summary of Upcoming Trials

Presenter: Nicolas M. Van Mieghem

June 06, 2024

Presentation NY Valves 2024

Patient Selection: From Clinical Trials to “On Label” to Real World – Who Are the Right Candidates for LAAO?

Presenter: Samir R. Kapadia

June 06, 2024

Presentation NY Valves 2024

Incidence, Predictors, and Management of Conduction Disturbances After Transcatheter Tricuspid Valve Replacement: The TRIPLACE Registry

Presenter: Andrea Scotti

June 06, 2024

Presentation NY Valves 2024

Surgical Mitral Valve Replacement With a Novel Polymeric Valve: 30-day Results From a Global Clinical Study of the Foldax TRIA Mitral Valve

Presenter: Isaac George

June 06, 2024

Presentation NY Valves 2024

Impact of Tricuspid Regurgitation on Right Heart Remodeling: Insights From the TRILUMINATE Pivotal MRI and CT Imaging Substudy

Presenter: Joao L. Cavalcante

June 06, 2024

Advertisement

1-Year and Landmark 6-12 Month Clinical Outcomes Among Patients in Complex Lesion Subsets Treated With DynamX Bioadaptor Compared to a Contemporary DES From the INFINITY-SWEDEHEART Randomized Clinical Trial

Artificial-Intelligence Enabled Quantitative CT Assessment of Atherosclerosis and Major Adverse Events: The Multi-Center International CONFIRM2 Registry

Too Good to Be True? Five Top Lessons of Major GLP-1 Agonists Trials

BedMed and BedMed-Frail randomized controlled trials

Mid-term Outcomes of Balloon Expandable TAVR for the Treatment of Failed Bioprosthetic Valves in the United States

Transcatheter Edge-to-Edge Repair vs Transcatheter Mitral Valve Replacement in Patients With Primary Mitral Regurgitation and Red Zone Anatomy: A Propensity Score-Matched Analysis

Evaluating Mitral TEER in the Management of Moderate Mitral Regurgitation Among Heart Failure Patients

Impact of Bioprosthetic Valve Performance on 5-year Clinical Outcomes in Patients at Intermediate or Greater Surgical Risk

UPDATES: Pre-emptive AVR Clinical Trials for Moderate and Severe AS

Managing Multi-Valvular Disease and Considerations for Surgical Eligibility

Assessing Functional Status and Predicting Clinical Improvement

The Importance of Baseline Hemodynamics and Tricuspid Anatomy

Real World TTVI Registries: Is There Concordance With the Randomized Trials?

T-TEER - TRILUMINATE

Transcatheter Tricuspid Valve Replacement - TRISCEND II

Pre-emptive AVR for Moderate AS and Asymptomatic Severe AS: A Summary of Upcoming Trials

Patient Selection: From Clinical Trials to “On Label” to Real World – Who Are the Right Candidates for LAAO?

Incidence, Predictors, and Management of Conduction Disturbances After Transcatheter Tricuspid Valve Replacement: The TRIPLACE Registry

Surgical Mitral Valve Replacement With a Novel Polymeric Valve: 30-day Results From a Global Clinical Study of the Foldax TRIA Mitral Valve

Impact of Tricuspid Regurgitation on Right Heart Remodeling: Insights From the TRILUMINATE Pivotal MRI and CT Imaging Substudy

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content